On September 10, 2026 Good Clean Clinical Care (GCCC) launched a microbiome-first telehealth platform for vaginal health, pairing lab testing with specialist consults and custom-compounded prescriptions. The Portland, Oregon company was founded by Wendy Strgar, who also founded lubricant brand Good Clean Love — making this one of the more direct examples yet of a sexual wellness consumer brand extending into regulated clinical care rather than adjacent retail.

Why It Matters

Two things make this more than another telehealth launch. The first is the direction of travel: a sexual wellness brand moving up the value chain into diagnostics and prescription compounding, rather than the usual pattern of a clinical company reaching down into consumer products. Good Clean Love has spent two decades selling a lubricant differentiated on osmolality and pH — the same argument now being made about a prescription base. That is a rare case of a consumer sexual wellness brand having accumulated genuine formulation IP it can carry into a regulated category. The second is that "Arousal, Pleasure & Comfort" appears in a clinical symptom taxonomy sitting next to UTIs and STIs. Sexual function has historically been the thing telehealth platforms address last, if at all, and usually under a wellness label to avoid regulatory friction. Treating it as one condition among many in a gynecological care pathway is the destigmatisation thesis actually showing up in product architecture. The caveats belong on the record. Compounded prescriptions occupy a different regulatory posture than FDA-approved drugs — they are not FDA-approved for safety and efficacy, and compounding pharmacies have drawn repeated enforcement attention this year, including in the sexual health category. The VENUS Study is company-affiliated research, and the $20 billion cost figure and recurrence statistic are the company's own framing. The commercial question is whether a testing-first model can beat the price and speed of the $30 telehealth prescription — and whether payers ever cover any of it.

The clinical model runs on a 56-target qPCR vaginal microbiome test. Patients complete testing, then meet virtually with clinicians the company describes as experienced in complex vaginal health, who read the results alongside symptoms and history before building a care plan. Where treatment is warranted, GCCC compounds prescriptions using BiomeNourish, a prescription base the company says was formulated specifically for vaginal and vulvar tissue and developed from more than two decades of its Bio-Match formulation work. The stated design principle is biomimicry: matching the pH and osmolality associated with a healthy vaginal microbiome rather than using what the company characterises as generic, hyperosmolar petroleum cream bases that can strip the vaginal lining.

"Women have spent far too long being told that recurring vaginal symptoms are something they just have to live with," Strgar said in the announcement. "For more than 20 years, I've been working to change the way we understand and care for the vaginal microbiome." GCCC cites an estimated $20 billion in annual US healthcare costs tied to vaginal health conditions and says more than half of women experience recurrence within six months of treatment for a vaginal infection — the repeat-antibiotic loop the platform is positioned against.

The science backing is attributed to the VENUS Study, led by Vaginal Biome Science and described by the company as examining the vaginal microbiome across 12 gynecological conditions at diagnosis. Kim Capone, PhD, GCCC's chief scientific officer, is named as VENUS lead researcher. The company's live storefront organises care by symptom across a notably broad surface: bacterial vaginosis and odor, yeast infections, vaginal dryness and genitourinary syndrome of menopause, vulvar and vestibular pain, UTIs, STIs, genital herpes, cancer-survivor vaginal symptoms, perianal pain — and, listed alongside the clinical categories, "Arousal, Pleasure & Comfort." Each prescription includes 12 months of clinician access, with free two-day discreet shipping.

Sources

Update — 2026-09-14

{Initial entry — story first created.}